Rare Diseases Today—March 19, 2026

This week’s Rare Diseases update highlights regulatory momentum, clinical progress, diagnostic expansion, partnership activity, and debate over evidence standards.

In Today’s Newsletter

Dive deeper

🧬 Otsuka reports adolescent PKU extension data for repinatrabit [1] [13 Mar 2026]

https://www.otsuka.co.jp/en/company/newsreleases/2026/20260313_1.html
Context: Otsuka presented open-label extension data in adolescents with phenylketonuria (PKU) and outlined the Phase 3 PheORD trial design in adults.
Key point: Repinatrabit (JNT-517; selective SLC6A19 inhibitor) reduced blood phenylalanine in the first adolescent cohort, with all participants described as clinical responders and no new treatment-related safety signal reported [1].
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Mirum completes Phase 3 EXPAND enrollment for LIVMARLI [2] [16 Mar 2026]

https://www.businesswire.com/news/home/20260316775084/en/Mirum-Pharmaceuticals-Completes-Enrollment-in-Phase-3-EXPAND-Study-of-LIVMARLI-maralixibat-in-Additional-Rare-Cholestatic-Liver-Diseases
Context: EXPAND is a randomized, double-blind, placebo-controlled Phase 3 study in patients aged 6 months or older with cholestatic pruritus across additional rare cholestatic liver diseases, including biliary atresia.
Key point: Mirum said enrollment is complete, with maralixibat being tested against placebo over 20 weeks and topline data expected in Q4 2026 [2].
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Natera launches Zenith Genomics for rare disease diagnosis [3] [US • 12 Mar 2026]

https://www.biospace.com/press-releases/natera-announces-commercial-launch-of-zenith-genomics-for-rare-disease-diagnosis
Context: Zenith Genomics is a whole-genome sequencing assay, built with technology developed by MyOme, and presented by Natera at ACMG 2026.
Key point: Natera commercially launched Zenith Genomics in the U.S. for rare disease diagnosis, positioning it as a whole-genome platform with added support for hard-to-detect features such as tandem repeat expansions [3].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🤝 NORD and OpenEvidence partner on AI-reviewed rare disease resources [4] [Worldwide • 12 Mar 2026]

https://www.morningstar.com/news/business-wire/20260312631955/national-organization-for-rare-disorders-and-openevidence-partner-to-bring-ai-powered-rare-disease-resources-to-clinicians-and-patients-worldwide
Context: The collaboration will combine AI-powered literature synthesis with expert review from specialists recommended by NORD, including experts from the Rare Disease Centers of Excellence Network.
Key point: NORD and OpenEvidence plan to build and maintain a library of more than 3,000 rare disease summaries for clinicians and patient audiences, with ongoing updates through OpenEvidence’s editorial system [4].
Implication: Access programs may expand screening, initiation, and follow-up at scale.

🏛️ Quoin wins FDA Fast Track for QRX003 in Netherton syndrome [5] [US • 11 Mar 2026]

https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-announces-fda-grants-fast-track
Context: QRX003 lotion (4%) is in two late-stage whole-body trials for Netherton syndrome, a rare genetic skin disorder with no approved treatments, according to Quoin.
Key point: FDA granted Fast Track designation to QRX003, adding to prior Pediatric Rare Disease and Orphan Drug designations in the U.S., plus EMA orphan designation [5].
Implication: Introduces a regulatory pathway that may speed development and review in a high-unmet-need setting.

🧫 Ultragenyx posts Phase 3 progress for DTX301 in OTC deficiency [6] [12 Mar 2026]

https://www.fiercebiotech.com/biotech/ultragenyx-gene-therapy-lessens-ammonia-levels-ph-3-rare-disease-win
Context: DTX301 is an AAV-based gene therapy for ornithine transcarbamylase (OTC) deficiency; the Phase 3 study enrolled 37 patients and uses co-primary endpoints.
Key point: Ultragenyx reported a statistically significant reduction in 24-hour plasma ammonia at 36 weeks versus placebo, meeting one co-primary endpoint; the second endpoint will be assessed later [6].
Implication: May influence prescriber choice and payer reviews pending full data.

📰 BioSpace examines what leucovorin’s CFD label expansion may, and may not, signal [7] [US • 17 Mar 2026]

https://www.biospace.com/fda/what-the-leucovorin-approval-signals-or-doesnt-about-the-fdas-rare-disease-stance
Context: The article contrasts FDA’s literature-based label expansion for leucovorin in ultrarare cerebral folate deficiency (CFD) with other recent rare disease rejections or complete response letters.
Key point: BioSpace says the leucovorin decision was unusual, relied on existing literature rather than new randomized data, and has intensified debate over consistency in FDA rare disease evidence standards [7].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧒 Sentynl licenses Progerinin for Hutchinson-Gilford progeria syndrome [8] [16 Mar 2026]

https://sentynl.com/news/sentynl-therapeutics-enters-into-agreement-with-prg-st-to-license-molecule-for-hutchinson-gilford-progeria-syndrome/
Context: Sentynl, a Zydus subsidiary, said Progerinin (SLC-D011) is an investigational oral small molecule for HGPS and that Phase 2A data are expected before the end of 1H 2026.
Key point: Sentynl entered an agreement with PRG S&T to license Progerinin for Hutchinson-Gilford progeria syndrome, with full rights tied to milestone conditions [8].
Implication: Signals pipeline investment and modality expansion.

💪 Aro reports positive Phase 1b topline for ABX1100 in late-onset Pompe disease [9] [17 Mar 2026]

https://www.biospace.com/press-releases/aro-biotherapeutics-reports-positive-phase-1b-topline-results-for-abx1100-a-muscle-targeted-gys1-sirna-in-patients-with-late-onset-pompe-disease-lopd
Context: ABX1100 is a muscle-targeted GYS1 siRNA tested as an add-on to enzyme replacement therapy in nine patients with late-onset Pompe disease, with 20-week follow-up.
Key point: Aro said ABX1100 achieved sustained GYS1 mRNA knockdown, showed early improvement in forced vital capacity in monitored patients, and was well tolerated with no serious adverse events or infusion reactions [9].
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Rare disease momentum remains broad, spanning metabolic disease, cholestatic liver disease, dermatology, neuromuscular disease, and progeria [1][2][5][8][9].
Several updates are developmental rather than definitive, including enrollment completion, Fast Track, partnership activity, and Phase 1b or interim Phase 3 readouts [2][5][6][8][9].
Regulatory flexibility remains a live theme, both in formal FDA pathway designations and in the debate over evidence standards highlighted by the leucovorin CFD expansion [5][7].
Diagnostics and information infrastructure are also moving, with Natera launching a rare disease genome assay and NORD partnering with OpenEvidence on AI-supported disease summaries [3][4].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Rare Disease archive on our research hub page

FAQ

What is repinatrabit, and what did Otsuka report in PKU?

Repinatrabit (JNT-517) is Otsuka’s investigational small-molecule SLC6A19 inhibitor for phenylketonuria. Otsuka reported adolescent open-label extension data showing reduced blood phenylalanine, and said the adult Phase 3 PheORD study is underway [1].

What does Mirum’s EXPAND enrollment milestone mean for LIVMARLI?

It means Mirum has fully enrolled its Phase 3 study testing maralixibat in additional rare cholestatic liver diseases beyond current approved settings. The key near-term milestone is topline data, expected in Q4 2026 [2].

What changed for QRX003 in Netherton syndrome?

FDA granted Fast Track designation to Quoin’s QRX003 lotion (4%). The product is already in late-stage clinical testing, and the designation may support more frequent FDA interaction and potentially faster review pathways [5].

Did Ultragenyx’s DTX301 already win Phase 3 in OTC deficiency?

Not fully yet. DTX301 met one co-primary endpoint, reduction in 24-hour plasma ammonia at 36 weeks, but the trial still needs to read out the second primary endpoint at a later timepoint [6].

Why is the leucovorin decision drawing attention in rare disease policy circles?

BioSpace argues the CFD label expansion was unusual because it relied on literature review rather than new randomized evidence. That has sharpened questions about whether FDA is applying rare disease evidence standards consistently across programs [7].

What stands out in Aro’s ABX1100 Pompe data?

The topline Phase 1b package included target knockdown, exploratory biomarker improvement, an early lung-function signal, and a favorable tolerability profile in a small add-on study. The company said these results will inform next development steps [9].

Entities / Keywords

Repinatrabit, JNT-517, Otsuka, phenylketonuria, PKU, SLC6A19 [1]
LIVMARLI, maralixibat, Mirum Pharmaceuticals, cholestatic pruritus, biliary atresia, IBAT [2]
Zenith Genomics, Natera, MyOme, whole-genome sequencing, rare disease diagnosis [3]
NORD, National Organization for Rare Disorders, OpenEvidence, rare disease summaries, AI-powered medical information [4]
QRX003, Quoin Pharmaceuticals, Netherton syndrome, Fast Track designation, Orphan Drug [5]
DTX301, Ultragenyx, OTC deficiency, ornithine transcarbamylase deficiency, AAV gene therapy [6]
Leucovorin, cerebral folate deficiency, CFD, FDA rare disease policy, label expansion [7]
Progerinin, SLC-D011, Sentynl, PRG S&T, Hutchinson-Gilford progeria syndrome, HGPS [8]
ABX1100, Aro Biotherapeutics, late-onset Pompe disease, LOPD, GYS1 siRNA, enzyme replacement therapy, ERT [9]